US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

41.83

+0.23370.56%

Post-market: 41.59-0.2337-0.56%19:30 EDT

Volume:208

Turnover:8.67K

Market Cap:31.37M

PE:- -

High:41.83

Open:41.59

Low:41.83

Close:41.59

52wk High:43.51

52wk Low:29.80

Shares:750.00K

Float Shares:750.00K

Volume Ratio:0.38

T/O Rate:0.03%

Dividend:0.14

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says

MT Newswires Live

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Centene (CNC), Natera (NTRA) and Vertex Pharmaceuticals (VRTX)

Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20

Niki BioSolutions Highlights Strategic Synergies in Alzheimer’s Diagnostics

Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027

THOMSON REUTERS

Cellectis pivots to in vivo gene editing and exits key CAR-T programs

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company

Natera Executive Chairman Matthew Rabinowitz Disposes of USD 16.32 Million in Common Shares

Bank of America Reveals 5.22% Indirect Stake in Qiagen

UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating

MT Newswires Live

Ligand CLO, Secretary Andrew Reardon Sells USD 1.43 Million in Common Shares

ABL Diagnostics Delivers Surging Profits as Scale‑Up Strategy Takes Hold

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co

Press Release: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Guardant Health's Breast Cancer Diagnostic Approved by US FDA

MT Newswires Live

Rothschild & Co Redburn Initiates Guardant Health at Buy

MT Newswires Live

Guardant Health initiated with a Buy at Rothschild & Co Redburn

Natera initiated with a Buy at Rothschild & Co Redburn

Krystal Biotech CEO Krish S. Krishnan Sells USD 7.59 Million in Common Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/HELX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":41.8273,"timestamp":1789502400000,"preClose":41.5936,"halted":0,"volume":208,"hourTrading":{"tag":"盘后","latestPrice":41.5936,"preClose":41.8273,"latestTime":"19:30 EDT","volume":8,"amount":334.151,"timestamp":1789515006138,"change":-0.2337,"changeRate":-0.005587,"amplitude":0},"delay":0,"changeRate":0.005618652869672231,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"Not Yet Opened","change":0.2337,"latestTime":"09-15 16:00:00 EDT","open":41.5936,"high":41.8273,"low":41.8273,"amount":8673.69984,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":0,"adr":0,"exchange":"CBOE","adjPreClose":41.5936,"sharesOutstanding":650000,"nav":41.622,"aum":31216701.03,"dividendRate":0.003381,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":41.5936,"preClose":41.8273,"latestTime":"19:30 EDT","volume":8,"amount":334.151,"timestamp":1789515006138,"change":-0.2337,"changeRate":-0.005587,"amplitude":0},"volumeRatio":0.3849,"impliedVol":0.0896,"impliedVolPercentile":0.3426},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.3849,"shares":750000,"dividePrice":0.1414,"high":41.8273,"amplitude":0,"preClose":41.5936,"low":41.8273,"week52Low":29.8,"pbRate":"--","week52High":43.5089,"institutionHeld":0,"latestPrice":41.8273,"eps":0,"divideRate":0.003381,"volume":208,"delay":0,"ttmEps":0,"open":41.5936,"prevYearClose":36.3062,"prevWeekClose":40.9874,"prevMonthClose":41.805,"prevQuarterClose":39.9651,"fiveDayClose":41.6426,"twentyDayClose":41.1366,"sixtyDayClose":35.8162},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667062145","title":"Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2667062145","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667062145?lang=en_us&edition=fundamental","pubTime":"2026-09-16 03:02","pubTimestamp":1789498945,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) stands to benefit from AstraZeneca's (AZN) failed Serena-4 trial because the result preserves the biomarker-driven monitoring approach supporting potential demand for its Guardant","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GNMX","LU0310800379.SGD","LU0889565916.HKD","AZN","GNOM","LU0289739699.SGD","LU1267930573.SGD","LU0058720904.USD","LU0708994859.HKD","BK4196","LU2237443978.SGD","LU0128525929.USD","EKG","LU2462157665.USD","LU1829250122.USD","LU2237443895.HKD","BK4585","BK4551","LU2237443465.HKD","LU2468319806.SGD","AZNH","BK4568","LU2456880835.USD","IE00B3T34201.USD","LU2237443622.USD","FFOX","LU0432979614.USD","LU0320765992.SGD","LU2237443549.SGD","BK4535","LU0109394709.USD","LU2417539215.USD","BK4007","LFSC","LU0029864427.USD","LU2237443382.USD","BK4588","GH","LU2089984988.USD","GDOC","PTH","LU2236285917.USD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667641173","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Centene (CNC), Natera (NTRA) and Vertex Pharmaceuticals (VRTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667641173","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667641173?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:20","pubTimestamp":1789471221,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Centene (CNC), Natera (NTRA) and Vertex Pharmaceut...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-centene-cnc-natera-ntra-and-vertex-pharmaceuticals-vrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-centene-cnc-natera-ntra-and-vertex-pharmaceuticals-vrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","LU0053671581.USD","BK4585","LU1035775433.USD","XLV","NTRA","LU0859254822.USD","CNC","LU0130518102.USD","GNMX","IBBQ","LU1291159041.SGD","HCSG","IE0002270589.USD","LU1988902786.USD","PBE","BK4023","LU0289739699.SGD","CNCG","LU0648000940.SGD","LU0823416689.USD","LU2065171311.SGD","TBXU","VRTX","BK4567","LABU","BK4139","IE0009355771.USD","IE00B19Z3581.USD","LU2236285917.USD","LU2462157665.USD","HELX","VERX","BK4137","LU1430594728.SGD","XBI","BK4581","IBB","IE00B19Z9Z06.USD","BIB","LU0234570918.USD","GNOM","LU1674673691.USD","LU0128526141.USD","BBH","LU0012050646.USD","LU2456880835.USD","LU1585245621.USD","LU2065169927.USD","BK4154"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667569983","title":"Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2667569983","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667569983?lang=en_us&edition=fundamental","pubTime":"2026-09-15 06:12","pubTimestamp":1789423938,"startTime":"0","endTime":"0","summary":"Guardant Health CIO Kumud Kalia disposes of 4,000 common shares worth $632,193.20Guardant Health Chief Information Officer Kumud Kalia sold 4,000 common shares on Sept. 11, 2026.The sale price was USD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL3DVtS3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","GNMX","GDOC","GH","LU0320765992.SGD","BK4535","BK4551","BK4585","GNOM","LU0109394709.USD","PTH","EKG","HELX","BK4196","FFOX","LFSC","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667869541","title":"Niki BioSolutions Highlights Strategic Synergies in Alzheimer’s Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2667869541","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667869541?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:37","pubTimestamp":1789418272,"startTime":"0","endTime":"0","summary":"Niki BioSolutions Inc ( ($NIKI) ) just unveiled an announcement. Niki BioSolutions Inc operates in the biotechnology and molecular diagnostics sect...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/niki-biosolutions-highlights-strategic-synergies-in-alzheimers-diagnostics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/niki-biosolutions-highlights-strategic-synergies-in-alzheimers-diagnostics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JDOC","HELX","RSPH","IEIH","LNGR","GNMX","DARP","BK4588","BBP","FHLC","SYNB","FWD","BMED","IBB","HTEC","XT","AGNG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667087693","title":"Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2667087693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667087693?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:07","pubTimestamp":1789416443,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nFWN4560HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4551","BK4585","GNOM","LU0109394709.USD","LU0320765992.SGD","FFOX","PTH","GH","LFSC","BK4588","HELX","BK4535","LU0889565916.HKD","GNMX","EKG","GDOC","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667376655","title":"Cellectis pivots to in vivo gene editing and exits key CAR-T programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2667376655","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667376655?lang=en_us&edition=fundamental","pubTime":"2026-09-14 15:15","pubTimestamp":1789370144,"startTime":"0","endTime":"0","summary":"Cellectis SA ( ($FR:ALCLS) ) has provided an announcement. Cellectis has approved a strategic shift to focus on in vivo gene editing, advancing two...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cellectis-pivots-to-in-vivo-gene-editing-and-exits-key-car-t-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cellectis-pivots-to-in-vivo-gene-editing-and-exits-key-car-t-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","HELX","SYNB","IDNA","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667653981","title":"Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2667653981","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667653981?lang=en_us&edition=fundamental","pubTime":"2026-09-14 14:40","pubTimestamp":1789368000,"startTime":"0","endTime":"0","summary":"Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectivelyTransformation supported by con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/14/3360712/0/en/cellectis-announces-strategic-transformation-to-in-vivo-gene-editing-company.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLLS","GNMX","SYNB","BK4156","BK4139","IDNA","HEAL","NC","HELX","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666508352","title":"Natera Executive Chairman Matthew Rabinowitz Disposes of USD 16.32 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2666508352","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666508352?lang=en_us&edition=fundamental","pubTime":"2026-09-12 09:35","pubTimestamp":1789176943,"startTime":"0","endTime":"0","summary":"Natera Executive Chairman Matthew Rabinowitz disposes of USD 16.32 million in common sharesNatera Executive Chairman Matthew Rabinowitz sold 50,000 common shares on Sept. 11, 2026 at about USD 325.01 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260912:nNDL6qGymP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera Executive Chairman Matthew Rabinowitz Disposes of USD 16.32 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNOM","LU0012050646.USD","LU0345770993.USD","LU2065169927.USD","NTRA","LU0053671581.USD","LU2065171402.SGD","LU1064131342.USD","LU0963586101.USD","LU2324357040.USD","LU2065170008.USD","LU0106261612.USD","BK4139","LU2264538146.SGD","LU0345770308.USD","LU1988902786.USD","HELX","LU2065171311.SGD","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666530163","title":"Bank of America Reveals 5.22% Indirect Stake in Qiagen","url":"https://stock-news.laohu8.com/highlight/detail?id=2666530163","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666530163?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:37","pubTimestamp":1788986261,"startTime":"0","endTime":"0","summary":"Qiagen ( ($QGEN) ) has issued an update. QIAGEN N.V., a Netherlands-based life sciences and biotechnology group focused on molecular diagnostics an...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bank-of-america-reveals-5-22-indirect-stake-in-qiagen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bank-of-america-reveals-5-22-indirect-stake-in-qiagen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FHLC","LU0256863902.USD","DARP","LU1804176565.USD","JDOC","RSPH","LU1366192091.USD","AGNG","LU2129689431.USD","LU0648001328.SGD","LU1718418525.SGD","IYF","XT","FNCL","LU0130517989.USD","LNGR","LU2133065610.SGD","HTEC","IYG","LU0070302665.USD","LU0321505868.SGD","LU1280957306.USD","IE00B1BXHZ80.USD","XLF","UYG","TFNS","BAC","LU1496350502.SGD","GNMX","IBB","BK4534","LU0256863811.USD","FWD","LU0648000940.SGD","IEIH","VFH","LU0314106906.USD","IE00BKVL7J92.USD","BK4582","SYNB","BMED","PGF","HELX","BBP","BK4581","FTXO","IE00B19Z3581.USD","LU1894683264.USD","KBWB","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666368655","title":"UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666368655","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666368655?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:35","pubTimestamp":1788960920,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $198.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EKG","FFOX","GDOC","HELX","BK4196","GNMX","BK4585","LU0320765992.SGD","PTH","BK4535","LU0109394709.USD","GNOM","BK4588","GH","LFSC","BK4551","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666308546","title":"Ligand CLO, Secretary Andrew Reardon Sells USD 1.43 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2666308546","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666308546?lang=en_us&edition=fundamental","pubTime":"2026-09-09 06:34","pubTimestamp":1788906885,"startTime":"0","endTime":"0","summary":"Ligand CLO, Secretary Andrew Reardon sells USD 1.43 million in common sharesLigand Pharmaceuticals CLO and Secretary Andrew Reardon sold 5,000 shares on Sept. 3.Sales priced at about $283.99 to $288.9","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL4zqMpT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Ligand CLO, Secretary Andrew Reardon Sells USD 1.43 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LGND","BK4139","HELX","LU0566484027.USD","LU1559883803.SGD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374809","title":"ABL Diagnostics Delivers Surging Profits as Scale‑Up Strategy Takes Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374809","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374809?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:05","pubTimestamp":1788887115,"startTime":"0","endTime":"0","summary":"The latest announcement is out from ABL Diagnostics SA ( ($FR:ABLD) ). ABL Diagnostics SA, a molecular diagnostics and healthcare software speciali...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abl-diagnostics-delivers-surging-profits-as-scaleup-strategy-takes-hold?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abl-diagnostics-delivers-surging-profits-as-scaleup-strategy-takes-hold?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VGT","TCAF","ABLD","HTEC","EKG","BMED","NOBL","HEAL","GNMX","BK4588","HELX","VHT","BK4585","BK4550","IGM","IXJ","QQH","CGCV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665373511","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665373511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665373511?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:51","pubTimestamp":1788871865,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amgen (AMGN), Guardant Health (GH) and Neurocrine (N...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-guardant-health-gh-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-guardant-health-gh-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","LU0823416689.USD","IBBQ","GNMX","LU2065170008.USD","AMGN","BK4137","LU0154245756.USD","LU0889565916.HKD","BK4588","GH","IBB","PTH","LU0058720904.USD","BK4139","EKG","NBIX","PBE","BK4533","BIB","LFSC","IE0002141913.USD","IE0009355771.USD","LU0109394709.USD","XBI","LU1057294990.SGD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU2242646821.SGD","GNOM","LU2468319806.SGD","PJP","LU1571399168.USD","TBXU","XLV","BBH","LU2242652126.USD","FFOX","GDOC","IE00BFTCPJ56.SGD","LU1061106388.HKD","HCSG","BK4585","LABU","IE00B2B36J28.USD","BK4599","LU0154245673.USD","HELX","LU0029874061.USD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378332","title":"Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378332","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378332?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:26","pubTimestamp":1788870360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","GNMX","LU0109394709.USD","GH","PTH","BK4585","HELX","LU0889565916.HKD","EKG","LU0320765992.SGD","BK4196","LFSC","BK4551","BK4535","FFOX","GNOM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665732264","title":"Press Release: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665732264","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665732264?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:01","pubTimestamp":1788865260,"startTime":"0","endTime":"0","summary":"Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical developmentAppointment strengthens executive leadership team as Editas","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAP","EDIT","IE00B7SZL793.SGD","BK4588","IDNA","WDNA","BK4585","IE0031619046.USD","IE00B19Z4B17.USD","HELX","BK4139","IE00B66KJ199.SGD","BK4214","GNMX","SYNB","BK4556","ASCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321994","title":"Guardant Health's Breast Cancer Diagnostic Approved by US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321994","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321994?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:08","pubTimestamp":1788862114,"startTime":"0","endTime":"0","summary":"Guardant Health's  Guardant360 CDx has been approved by the US Food and Drug Administration as a companion diagnostic for advanced metastatic breast cancer, the company said Friday.The specific indication for the diagnostic combination is to identify patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with specific mutations before radiographic progression who may benefit from treatment with AstraZeneca's  Etcamah, the company said.The approval is based on data from a clinical trial showing a 56% reduction in the risk of progression or death, the company said.Shares of the company were up 1% in recent premarket trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GNOM","AZN","LU2237443382.USD","LU2089984988.USD","LU0109394709.USD","LU0058720904.USD","PTH","LU2237443622.USD","LU2462157665.USD","LU2456880835.USD","LU1267930573.SGD","GDOC","LABU","LU2237443978.SGD","BK4551","IE00B3T34201.USD","LU0320765992.SGD","BK4535","LU2237443549.SGD","EKG","LU0889565916.HKD","LU2236285917.USD","LFSC","LU0432979614.USD","BK4568","BK4196","AZNH","LU2237443465.HKD","LU0289739699.SGD","LU0029864427.USD","GH","BK4585","LU2468319806.SGD","FFOX","BK4588","LU1829250122.USD","GNMX","LU0128525929.USD","LU2417539215.USD","LU0310800379.SGD","LU2237443895.HKD","HELX","BK4007","LU0708994859.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665213403","title":"Rothschild & Co Redburn Initiates Guardant Health at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2665213403","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665213403?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:01","pubTimestamp":1788861705,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $198.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LFSC","PTH","EKG","BK4585","LU0320765992.SGD","GNOM","GNMX","LU0889565916.HKD","GDOC","FFOX","BK4196","BK4588","BK4551","LU0109394709.USD","HELX","GH","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665532615","title":"Guardant Health initiated with a Buy at Rothschild & Co Redburn","url":"https://stock-news.laohu8.com/highlight/detail?id=2665532615","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665532615?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:16","pubTimestamp":1788858969,"startTime":"0","endTime":"0","summary":"Rothschild & Co Redburn initiated coverage of Guardant Health (GH) with a Buy rating and $203 price target The firm says Guardant is the leader in ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-initiated-with-a-buy-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-initiated-with-a-buy-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","LU0889565916.HKD","BK4585","GNOM","LU0109394709.USD","EKG","GH","GNMX","BK4196","PTH","GDOC","LFSC","HELX","BK4551","FFOX","BK4535","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326489","title":"Natera initiated with a Buy at Rothschild & Co Redburn","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326489","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665326489?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:15","pubTimestamp":1788858958,"startTime":"0","endTime":"0","summary":"Rothschild & Co Redburn initiated coverage of Natera (NTRA) with a Buy rating and $385 price target Natera is the market leader in molecular residu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/natera-initiated-with-a-buy-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/natera-initiated-with-a-buy-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNOM","BK4139","LU0106261612.USD","LU0012050646.USD","LU0963586101.USD","LU2324357040.USD","NTRA","LU2065170008.USD","LU2264538146.SGD","LU2065171402.SGD","HELX","LU0345770993.USD","LU2065169927.USD","LU0053671581.USD","LU2065731478.USD","LU0345770308.USD","LU1988902786.USD","LU2065171311.SGD","LU1064131342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665352961","title":"Krystal Biotech CEO Krish S. Krishnan Sells USD 7.59 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2665352961","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665352961?lang=en_us&edition=fundamental","pubTime":"2026-09-05 07:15","pubTimestamp":1788563709,"startTime":"0","endTime":"0","summary":"Krystal Biotech CEO Krish S. Krishnan sells USD 7.59 million in common sharesKrish S. Krishnan, president, CEO, director, sold 25,000 Krystal Biotech common shares on Sept. 4, 2026.Sales prices cluste","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL3bqQgC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Krystal Biotech CEO Krish S. Krishnan Sells USD 7.59 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","HELX","BK4139","PSCH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}